

22 February 2017

Press release

As of February 20th 2017 Helene Kähler Hjenner is the new CEO of Immudex. Helene Kähler Hjenner has worked within biotech and medtech for more than 15 years, as managing director, project leader and co-founder of upstart companies. Helene Kähler Hjenner is trained as a chemical engineer and cand. scient. in human biology. Helene Kähler Hjenner has been an investor in Immudex for a number of years and as such she has obtained insight into Immudex operations.

Helene Kähler Hjenner succeeds Henrik Pedersen, co-founder and previous CEO of Immudex. Henrik Pedersen is now looking forward to challenge himself in other areas. “After 20 years in biotech companies, it will be great to move on to something different. I have some ideas, but no definite plans to be executed yet”, says Henrik Pedersen.

Chairman of the board at Immudex, Søren Elmann Ingerslev, is confident that Helene Kähler Hjenner with her experience and commitment is the right person to continue the successful development of Immudex together with existing members of the management team - Liselotte Brix and Stephen Haley - and the very competent people in the Immudex organisation.

About Immudex

Based in Copenhagen, Denmark, with North American operations based in Fairfax, Virginia, Immudex provides MHC Dextramers for the monitoring of antigen-specific T cells. Under an agreement with the US Cancer Immunotherapy Consortium (CIC) and the European Cancer Immunotherapy Consortium (CIMT), Immudex also provides MHC Multimer and Elispot proficiency panel services worldwide.